脑血管病是威胁人类健康的最严重的疾病之一,脑梗死虽比脑出血病死率低,但致残率高,且大约20%的幸存者在1～2年内会再次复发,使患者的生存质量严重下降。近年来,国内外普遍开展了溶栓治疗急性脑梗死的临床研究,但溶栓治疗的安全时间窗、溶栓剂的选择、剂量、给药途径与疗效的关 Cerebrovascular disease is one of the most serious diseases that threaten human health. Although cerebral infarction has a lower mortality rate than cerebral hemorrhage, its morbidity is high and about 20% of survivors will relapse within one to two years so that patients A serious decline in the quality of life. In recent years, clinical research on thrombolytic therapy for acute cerebral infarction has been widely carried out in both home and abroad. However, the safe window of thrombolytic therapy, the choice of thrombolytic agent, dosage, the route of administration and the effect